KellBenx Raises $2.5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Startup biotech firm KellBenx today announced it has raised $2.5 million in an initial funding round.

Four investors participated in the round, three undisclosed venture capital groups and an undisclosed angel investor.

"The funds will be used to launch an [institutional review board]-approved clinical trial and build our Long Island laboratory to analyze the data we are producing," Hassan Bennani, CEO of KellBenx, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.